Share：
Share this content in WeChat
X
[Chinese] [PDF] 573 1
• Clinical Article •
Predictive value of DCE-MRI and TIC combined ADC models for the expression status of hormone receptors in mass-type breast cancer
ZHAN Dan  YANG Yu 

Cite this article as: ZHAN D, YANG Y. Predictive value of DCE-MRI and TIC combined ADC models for the expression status of hormone receptors in mass-type breast cancer[J]. Chin J Magn Reson Imaging, 2025, 16(9): 90-95. DOI:10.12015/issn.1674-8034.2025.09.014.


[Abstract] Objective To explore the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), time-signal intensity curve (TIC), and apparent diffusion coefficient (ADC) in predicting the expression status of hormone receptors (HR) in breast cancer, and to evaluate the correlation and predictive value between MRI features and hormone receptor status.Materials and Methods The MRI findings of 206 patients with pathologically confirmed invasive breast cancer from November 2019 to March 2025 were retrospectively analyzed, and the differences of morphological signs, TIC and ADC values in different HR expression states (HR+/HR-) breast cancer in DCE-MRI were analyzed. Multivariate regression analysis of univariate and multivariate MRI findings with statistical significance was performed, a logistic regression model was established, and ROC curve was drawn, evaluating the efficacy of MRI features in predicting the expression status of hormone receptors in breast cancer.Results The morphological features (including tumor maximum diameter, margin, burr sign and enhancement mode), TIC and ADC in HR+ group and HR- group were statistically significant (P < 0.05), and HR+ was more likely to show maximum diameter ≤ 2 cm, blurred edges, burrs and uneven enhancement, and TIC was a type Ⅲ curve. And the average ADC value is lower than HR-. MRI morphological features (including maximum meridian, burr, enhancement mode) and ADC values can predict hormone receptor-positive and negative breast cancer, and the area under the curve (AUC) was 0.806 (95% CI: 0.747 to 0.864), 0.669 (95% CI: 0.593 to 0.744), the sensitivities were 74.1% and 75.3%, and the specificities were 74.4% and 51.2%, respectively, while the AUC for the combined predicting of HR expression status was 0.837 (95% CI: 0.784 to 0.890), the sensitivity, specificity and accuracy were 84.0%, 65.6%, respectively, among which MRI morphological features combined with ADC value had the highest value.Conclusions The combined model of MRI morphological features and ADC values has a good predictive value for the expression status of hormone receptors in breast cancer, thereby providing a basis for the formulation and adjustment of clinical treatment plans.
[Keywords] breast cancer；hormone receptor；dynamic contrast-enhanced magnetic resonance imaging；time-signal intensity curve；apparent diffusion coefficient；predictive value

ZHAN Dan   YANG Yu*  

Department of Radiology, the First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China

Corresponding author: YANG Y, E-mail: 178693936@qq.com

Conflicts of interest   None.

Received  2025-02-24
Accepted  2025-09-03
DOI: 10.12015/issn.1674-8034.2025.09.014
Cite this article as: ZHAN D, YANG Y. Predictive value of DCE-MRI and TIC combined ADC models for the expression status of hormone receptors in mass-type breast cancer[J]. Chin J Magn Reson Imaging, 2025, 16(9): 90-95. DOI:10.12015/issn.1674-8034.2025.09.014.

[1]
WU H, LÜ Q. Epidemiological trends and implications of breast cancer prevention and control in China and the world: an interpretation of the Global Cancer Statistics Report 2018–2022[J]. Chin J Bases Clin Gen Surg, 2024, 31(7): 796-802. DOI: 10.7507/1007-9424.202407031.
[2]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[3]
Breast Cancer Professional Committee of Chinese Anti-Cancer Association, Breast Oncology Group of Chinese Medical Association Oncology Branch. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, 33(12): 1092-1187. DOI: 10.19401/j.cnki.1007-3639.2023.12.004.
[4]
XU K, WANG R T, XIE H, et al. Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis[J/OL]. Oncogenesis, 2021, 10(10): 66 [2025-02-23]. https://pubmed.ncbi.nlm.nih.gov/34611125/. DOI: 10.1038/s41389-021-00355-6.
[5]
MA Y, LIU A D, O'CONNELL A M, et al. Contrast-enhanced cone beam breast CT features of breast cancers: correlation with immunohistochemical receptors and molecular subtypes[J]. Eur Radiol, 2021, 31(4): 2580-2589. DOI: 10.1007/s00330-020-07277-8.
[6]
LIU H Y. Diagnostic value of dynamic contrast-enhanced MRI and diffusion-weighted imaging in breast cancer[J]. Jilin Med J, 2024, 45(8): 1847-1849. DOI: 10.3969/j.issn.1004-0412.2024.08.018.
[7]
ZHANG Y W, ZHENG S Y, WANG X R, et al. Correlation between 3.0 T MRI features and Ki-67 expression in breast cancer[J]. Diagn Imag Interv Radiol, 2023, 32(3): 182-187. DOI: 10.3969/j.issn.1005-8001.2023.03.004.
[8]
American College of Radiology(ACR). ACR breast imaging reporting and data system,breast imaging atlas[M].Reston: American College of Radiology,2013:27-32.
[9]
PENG J, HONG Y, CHEN Q T, et al. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1347762 [2025-02-23]. https://pubmed.ncbi.nlm.nih.gov/38567311/. DOI: 10.3389/fendo.2024.1347762.
[10]
MA L Q, LIU L, HAN Z G, et al. MRI characteristics and their relationship with PR, ER and CerbB-2 in patients with breast cancer[J]. Chin J CT MRI, 2024, 22(7): 105-107. DOI: 10.3969/j.issn.1672-5131.2024.07.033.
[11]
LONG N, RAN C, SUN J, et al. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes[J]. Eur Rev Med Pharmacol Sci, 2020, 24(22): 11518-11527. DOI: 10.26355/eurrev_202011_23793.
[12]
ALLISON K H, HAMMOND M E H, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update[J]. J Clin Oncol, 2020, 38(12): 1346-1366. DOI: 10.1200/JCO.19.02309.
[13]
JIANG S E, XU H Y. Relationship between expression of ER, PR and Ki67 and clinicopathology in breast cancer[J]. Shenzhen J Integr Tradit Chin West Med, 2019, 29(24): 93-95. DOI: 10.16458/j.cnki.1007-0893.2019.24.045.
[14]
SEYFETTIN A, DEDE I, HAKVERDI S, et al. MR imaging properties of breast cancer molecular subtypes[J]. Eur Rev Med Pharmacol Sci, 2022, 26(11): 3840-3848. DOI: 10.26355/eurrev_202206_28951.
[15]
GAO Y, WANG P F, YAO L, et al. Correlation between the expressions of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 of patients with breast cancer and their magnetic resonance imaging (MRI) signs[J]. Chin J Fam Plan, 2024, 32(4): 948-952, 969. DOI: 10.3969/j.issn.1004-8189.2024.04.045.
[16]
LI Y L, AN S Y, ZHANG P L, et al. Study of molecular markers expression and pathological diagnosis in invasive ductal carcinoma of mammary glands[J]. Syst Med, 2022, 7(8): 11-15. DOI: 10.19368/j.cnki.2096-1782.2022.08.011.
[17]
RELLA R, BUFI E, BELLI P, et al. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy[J]. Diagn Interv Imaging, 2022, 103(10): 486-494. DOI: 10.1016/j.diii.2022.04.004.
[18]
ZHAN D, HHANG Y F, LI P, et al. The diagnostic value of multimodal MRI in triple-negative and non-triple-negative breast cancer[J]. Journal of Practical Radiology, 2021, 37(9): 1455-1458. DOI: 10.3969/j.issn.1002-1671.2021.09.013.
[19]
MOO T A, SACCARELLI C R, SUTTON E J, et al. Tumor-nipple distance of ≥ 1 cm predicts negative nipple pathology after neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2021, 28(11): 6024-6029. DOI: 10.1245/s10434-021-09902-2.
[20]
HAO L L. Clinical case-control study of triple negative breast cancer and basal cell-like breast cancer[J]. Shenzhen J Integr Tradit Chin West Med, 2019, 29(20): 90-92. DOI: 10.16458/j.cnki.1007-0893.2019.20.043.
[21]
HUANG J L, LIN Q, CUI C X, et al. Correlation between imaging features and molecular subtypes of breast cancer in young women (≤30 years old)[J]. Jpn J Radiol, 2020, 38(11): 1062-1074. DOI: 10.1007/s11604-020-01001-8.
[22]
DAI T, SU T, WANG R, et al. Predictive value of DCE-MRI features of breast cancer on hormone receptor, HER-2 and triple negative breast cancer[J]. Chin J Magn Reson Imag, 2023, 14(4): 57-67. DOI: 10.12015/issn.1674-8034.2023.04.011.
[23]
KANG S R, KIM H W, KIM H S. Evaluating the relationship between dynamic contrast-enhanced MRI (DCE-MRI) parameters and pathological characteristics in breast cancer[J]. J Magn Reson Imaging, 2020, 52(5): 1360-1373. DOI: 10.1002/jmri.27241.
[24]
WANG X L, XIA Y M, ZHANG Y, et al. The value of marginal signs in the differential diagnosis of benign and malignant breast masses[J]. J Pract Med Imag, 2019, 20(5): 445-447. DOI: 10.16106/j.cnki.cn14-1281/r.2019.05.005.
[25]
XUE F, JIANG J. Dynamic enhanced magnetic resonance imaging versus ultrasonic diffused optical tomography in early diagnosis of breast cancer[J/OL]. J Healthc Eng, 2022, 2022: 4834594 [2025-02-24]. https://pubmed.ncbi.nlm.nih.gov/35449832/. DOI: 10.1155/2022/4834594.
[26]
LI W B, CHANG Y W, BAI X H, et al. Comparison of the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy for improving prognosis in triple-negative breast cancer patients[J]. Am J Transl Res, 2024, 16(8): 3978-3989. DOI: 10.62347/VHME8736.
[27]
HUANG G L, DU S Y, GAO S, et al. Molecular subtypes of breast cancer identified by dynamically enhanced MRI radiomics: the delayed phase cannot be ignored[J/OL]. Insights Imaging, 2024, 15(1): 127 [2025-02-24]. https://pubmed.ncbi.nlm.nih.gov/38816553/. DOI: 10.1186/s13244-024-01713-9.
[28]
WU J F, GUI Z H, YAN H. Comparison of human epidermal growth factor receptor-2gene amplification status and protein expression in invasive breast carcinoma and its correlation with clinicopathological characteristics[J]. J Clin Med Pract, 2021, 25(13): 40-44. DOI: 10.7619/jcmp.20211659.
[29]
YANG Z Q, CHEN X F, ZHANG T H, et al. Quantitative multiparametric MRI as an imaging biomarker for the prediction of breast cancer receptor status and molecular subtypes[J/OL]. Front Oncol, 2021, 11: 628824 [2025-02-24]. https://pubmed.ncbi.nlm.nih.gov/34604024/. DOI: 10.3389/fonc.2021.628824.
[30]
WANG J, TANG W W, TIAN Z F, et al. Correlation between DCE-MRI parameters/ADC and pathological molecular prognostic markers of breast cancer[J]. Chin J Magn Reson Imag, 2021, 12(3): 76-79. DOI: 10.12015/issn.1674-8034.2021.03.017.
[31]
YUAN C R, JIN F, GUO X L, et al. Correlation analysis of breast cancer DWI combined with DCE-MRI imaging features with molecular subtypes and prognostic factors[J/OL]. J Med Syst, 2019, 43(4): 83 [2025-02-23]. https://pubmed.ncbi.nlm.nih.gov/30810823/. DOI: 10.1007/s10916-019-1197-5.
[32]
JIANG J R, CHEN F, HUANG Q C, et al. Correlation analysis between ADC value and molecular expression in diffusion-weighted MRI of invasive breast cancer[J]. China Med Pharm, 2023, 13(17): 160-164. DOI: 10.20116/j.issn2095-0616.2023.17.38.
[33]
FUSCO R, GRANATA V, MATTACE RASO M, et al. Blood oxygenation level dependent magnetic resonance imaging (MRI), dynamic contrast enhanced MRI, and diffusion weighted MRI for benign and malignant breast cancer discrimination: a preliminary experience[J/OL]. Cancers (Basel), 2021, 13(10): 2421 [2025-02-23]. https://pubmed.ncbi.nlm.nih.gov/34067721/. DOI: 10.3390/cancers13102421.
[34]
CHOI S E, PARK A Y, KIM G I, et al. The kinetic parameters of dynamic contrast-enhanced MRI with ultrafast imaging in breast cancer patients receiving neoadjuvant chemotherapy: Prediction of pathologic complete response and correlation with histologic microvessel density[J/OL]. Medicine (Baltimore), 2025, 104(5): e40239 [2025-02-23]. https://pubmed.ncbi.nlm.nih.gov/39889156/. DOI: 10.1097/MD.0000000000040239.
[35]
ZHANG Y. Application of DWI combined with dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of breast cancer[J]. J Imag Res Med Appl, 2021, 5(24): 98-100. DOI: 10.3969/j.issn.2096-3807.2021.24.034.

PREV Application of cardiac magnetic resonance tissue tracking and T1 mapping technology in the assessment of diabetic myocardial injury
NEXT Development and validation of an intratumoral and peritumoral deep learning radiomics model based on DCE-MRI for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer: A multicenter study
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn